Race against time: The export of essential medicines to rwanda
Public Health Ethics 1 (2):89-103 (2008)
| Abstract | Matthew Rimmer, ACIPA, The Australian National University, College of Law, Canberra, ACT, 0200, Australia. Tel.: (02) 61254164; Email: matthew.rimmer{at}anu.edu.au ' + u + '@' + d + ' '//--> Abstract This article considers the significance of the first export of essential medicines under the WTO General Council Decision 2003. In July 2007, Rwanda became the first country to provide a notification under the WTO General Council Decision 2003 of its intent to import a fixed-dose, triple combination HIV/AIDS drug manufactured by the Canadian generic pharmaceutical manufacturer Apotex, Inc. In September 2007, Apotex was granted the first compulsory licence application under Canada's Access to Medicines Regime. This article considers the convoluted and protracted negotiations between the Government of Rwanda, Apotex and three patent holders, GlaxoSmithKline, Boehringer Ingleheim Canada and Shire BioChemical, Inc. It questions the efficiency of this process. This article considers the review of the Jean Chrétien Pledge to Africa Act 2004 (Canada). It is critical of the refusal of the Conservative Government of Canada to make any amendments to the legislation to improve the cost-effective delivery of essential medicines. This article queries the proposed Hong Kong Amendment to the TRIPS Agreement 1994, given the concerns of the Africa Group. It is submitted that it is undesirable to codify the WTO General Council Decision 2003, given its failure to provide a speedy, efficient and cost-effective delivery of essential medicines. CiteULike Connotea Del.icio.us What's this? | |||||||||
| Keywords | No keywords specified (fix it) | |||||||||
| Categories | ||||||||||
| Options |
|
|||||||||
Download options| PhilPapers Archive |
Upload a copy of this paper Check publisher's policy on self-archival Papers currently archived: 5,631 |
| External links |
 |
| Through your library | Configure |
Similar books and articlesBetty B. Chaar & Johnson Lee (2012). Role of Socioeconomic Status on Consumers' Attitudes Towards DTCA of Prescription Medicines in Australia. Journal of Business Ethics 105 (4):447-460.
Matthew Lee & Jillian Kohler (forthcoming). Benchmarking and Transparency: Incentives for the Pharmaceutical Industry's Corporate Social Responsibility. Journal of Business Ethics.
Robert C. Bird (2009). Developing Nations and the Compulsory License: Maximizing Access to Essential Medicines While Minimizing Investment Side Effects. Journal of Law, Medicine and Ethics 37 (2):209-221.
Rudolf V. van Puymbroeck (2010). Basic Survival Needs and Access to Medicines – Coming to Grips with TRIPS: Conversion + Calculation. Journal of Law, Medicine and Ethics 38 (3):520-549.
Klaus M. Leisinger (2009). Corporate Responsibilities for Access to Medicines. Journal of Business Ethics 85:3 - 23.
Thomas Alured Faunce & Hitoshi Nasu (2008). Three Proposals for Rewarding Novel Health Technologies Benefiting People Living in Poverty. A Comparative Analysis of Prize Funds, Health Impact Funds and a Cost-Effectiveness/Competitive Tender Treaty. Public Health Ethics 1 (2):146-153.
Michael Ravvin (2008). Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions. Public Health Ethics 1 (2):110-123.
N. Craig Smith & Anne Duncan (2005). GlaxoSmithKline and Developing Country Access to Essential Medicines (A). Journal of Business Ethics Education 2 (1):97-121.
Devi Sridhar (2008). Improving Access to Essential Medicines: How Health Concerns Can Be Prioritised in the Global Governance System. Public Health Ethics 1 (2):83-88.
N. Craig Smith & Anne Duncan (2005). GlaxoSmithKline and Access to Essential Medicines (B). Journal of Business Ethics Education 2 (1):123-132.
Analytics
Monthly downloads |
Added to index2009-12-21Total downloads2 ( #232,211 of 548,941 )Recent downloads (6 months)0How can I increase my downloads? |
My notes
Discussion
